MELA Sciences (NASDAQ:MELA)

CAPS Rating: 1 out of 5

A medical device company which focuses on designing and development of a non-invasive, point-of-care instrument to assist in the early diagnosis of melanoma.

Recs

1
Player Avatar JonPon (< 20) Submitted: 9/10/2010 11:13:32 AM : Outperform Start Price: $6.66 MELA Score: -157.71

With the accuracy of the MELAFind device being statistically significant in comparison with dermatologists and with it's non-invasive nature it is sure to be a winning device.

Member Avatar jrusso9722 (< 20) Submitted: 10/7/2010 4:11:13 PM
Recs: 0

MelaFind works to a standard, equal in every doctor's office, in the world. 5 million doctors, across the world, each look at a mole differently, and, they cannot look below the dermis. MelaFind looks below the dermis. This imaging device is a stable "platform" from which to make decisions, improving the lives of the people who suspect, or have, melanoma. Just like X-rays, MRI, CAT scans, etc., nothing is perfect. FDA must consider the help this device will provide. 120,000 new melanoma cases each year. FDA must approve in November 2010. If a member of the FDA Committee was afflicted with this disease, or suspected it, or have a loved one with suspicious moles, etc. THAT FDA MEMBER would want MelaFind to be approved. It's a tool that cannot hurt, it can only help. AND, SINCE THERE IS NO CURE FOR METASTIC MELANOMA, HOW CAN THIS DIAGNOSTIC TOOL NOT BE OFFERED TO DOCTORS, TO SAVE LIVES. My wife is a Melanoma victim,she had surgery to remove a melanoma Stage I mole. They removed a large section of muscle tissue. I want her doctor to chart her body with MelaFind. Regards, Joe

Featured Broker Partners


Advertisement